J. Goldman & Co’s Sarepta Therapeutics SRPT Stock Holding History

J. Goldman & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$163K	Buy	+7,500	New	+$145K	﹤0.01%	605
2025 Q2	–	Sell	-20,000	Closed	-$1.28M	–	633
2025 Q1	$1.28M	Buy	+20,000	New	+$2.11M	0.03%	343
2024 Q3	–	Sell	-81,500	Closed	-$12.9M	–	607
2024 Q2	$12.9M	Buy	+81,500	New	+$10.5M	0.36%	91
2019 Q4	–	Sell	-28,000	Closed	-$2.11M	–	348
2019 Q3	$2.11M	Buy	+28,000	New	+$3.31M	0.16%	153
2017 Q4	–	Sell	-45,500	Closed	-$2.06M	–	429
2017 Q3	$2.06M	Sell	45,500 -6,500	-13%	-$260K	0.1%	192
2017 Q2	$1.75M	Sell	52,000 -53,000	-50%	-$1.73M	0.1%	190
2017 Q1	$3.11M	Sell	105,000 -102,500	-49%	-$3.17M	0.15%	174
2016 Q4	$5.69M	Buy	+207,500	New	+$8.33M	0.38%	85
2016 Q3	–	Sell	-92,500	Closed	-$1.76M	–	389
2016 Q2	$1.76M	Buy	+92,500	New	+$1.71M	0.09%	208
2015 Q4	–	Sell	-140,000	Closed	-$4.5M	–	297
2015 Q3	$4.5M	Buy	+140,000	New	+$4.75M	0.39%	84
2013 Q4	–	Sell	-50,000	Closed	-$2.36M	–	289
2013 Q3	$2.36M	Sell	50,000 -27,500	-35%	-$1.06M	0.22%	144
2013 Q2	$2.95M	Buy	+77,500	New	+$2.77M	0.3%	112

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's SRPT Position: Q1 2025 in Review

J. Goldman & Co sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 87,866 shares — an estimated $9.25M sold.

J. Goldman & Co first reported a position in SRPT in Q3 2015 and held it in 14 quarters. The position peaked at $12.4M in Q3 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

J. Goldman & Co reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
J. Goldman & Co sold 87,866 Sarepta Therapeutics shares in Q1 2025, an estimated $9.25M.
J. Goldman & Co first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 14 quarters.
J. Goldman & Co's Sarepta Therapeutics position peaked at $12.4M in Q3 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on J. Goldman & Co's 13F filing for Q1 2025, filed 15 May 2025.